Tech Company Financing Transactions
Gallant Therapeutics Funding Round
Gallant Therapeutics, based in San Diego, scored $15 million in investment from Bold Capital Partners and Digitalis Ventures.
Transaction Overview
Company Name
Announced On
1/8/2024
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series A
Investors
Bold Capital Partners (Lead Investor) (Teymour Boutros-Ghali)
Digitalis Ventures (Cindy Cole)
Proceeds Purpose
The successful funding round will enable Gallant to accelerate the development of its pipeline of potentially first-in-class allogeneic stem cell therapeutics, focusing on achieving conditional FDA approval for its leading therapeutic candidate targeting FCGS, a deadly disease with a high unmet medical need.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
10865 Road to the Cure 101
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Undisclosed
Website
Email Address
Overview
We are leaders in veterinary regenerative medicine, with deep industry experience in cell therapy development and commercialization and a love of and commitment to animals.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Teymour Boutros-Ghali
Chief Executive Officer
Linda Black
Chief Technical Officer
Carolyn Wrightson
General Manager
Beau Becker
VP - Finance
April Treadwell
VP - Regulatory Affairs
Valentine Williams
Browse more venture capital transactions:
Prev: 1/8/2024: Vortexa venture capital transaction
Next: 1/8/2024: Second Dinner Studios venture capital transaction
Share this article
News on VC Transactions
We do our best to record funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs